Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Onset Malignancies Initiative (EOMI): Molecular Profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate Among Racially and Ethnically Diverse Populations

NCT04955808 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT04955808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04955808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Onset Malignancies Initiative (EOMI): Molecular Profiling of Breast, Colon, Kidney, Liver, Multiple Myeloma, and Prostate Among Racially and Ethnically Diverse Populations
Lead sponsor
National Cancer Institute (NCI)
Phase
Observational
Overall status
Suspended
Start date
February 7, 2017
Completion date
December 31, 2026
Enrollment
2,400 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast carcinoma, colon carcinoma, invasive carcinoma, kidney carcinoma, liver carcinoma, malignant solid neoplasm, multiple myeloma, prostate carcinoma